Beam Therapeutics
Market cap $2.14B 103.5M shares (10-Q, Oct 27, 2026) × $20.65 close Nov 17, 2026
Most recent annual filing: 2026-02-24
- BEAM-304 IND filing2026BEAM-304 IND filing, 2026, notable
- risto-cel BLA filingyear-end 2026risto-cel BLA filing, year-end 2026, major
- risto-cel manufacturing updateas early as year-end 2026risto-cel manufacturing update, as early as year-end 2026, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (6 active programs)
BEAM-302
BEAM-304
BEAM-301
BEAM-103
- Undisclosed indication
BEAM-102
- Undisclosed indication
Technology platforms
ESCAPE
Engineered Stem Cell Antibody Paired Evasion — non-genotoxic conditioning platform combining antibody-based conditioning with multiplex gene edited HSCs; applicable ex vivo or in vivo including for sickle cell disease
Targets: CD117
Base Editing Platform
Proprietary base editing technology enabling precision genetic medicines that target a single base in the genome without double-stranded DNA breaks, using CRISPR-guided deaminase enzymes. Supports ex vivo and in vivo delivery modalities across hematology and other disease areas including sickle cell disease and beta-thalassemia.
Apellis Complement Base Editing Collaboration · Apellis Pharmaceuticals
Research collaboration using Beam's base editing technology to discover treatments for complement system-driven diseases across six programs targeting specific genes in the complement system in various organs including the eye, liver, and brain. Apellis holds exclusive option rights to license any or all programs.
Capital (as filed)
- Cash
- $213M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $831M Sep 30, 2026
- Operating cash flow
- −$111M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $1.15B cash, runway mid-2029 per the update of Sep 8, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (7)
- 2026-11-11 UPDATE: Beam Therapeutics (BEAM) - The Permission Slip Gets Signed 🔒 Paid
- 2026-10-28 UPDATE: Beam Therapeutics (BEAM) - Off the Cornstarch ★ Distilled Pro
- 2026-10-14 UPDATE: Beam Therapeutics (BEAM) - The Second Liver Bet Shows Its Hand ★ Distilled Pro
- 2026-09-08 UPDATE: Beam Therapeutics (BEAM) - Barcelona Answers the Liver Question 🔒 Paid
- 2026-08-04 UPDATE: Beam Therapeutics (BEAM) - The Pivotal Cohort Opens, The Stock Doesn’t Care 🔒 Paid
- 2026-06-18 UPDATE: Beam Therapeutics (BEAM) - The Third Liver Bet Goes Clinical 🔒 Paid
- 2026-04-24 Beam Therapeutics (BEAM) - Scientific Deep Dive for Risto-cel and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (7 calls)
Every verdict Biotech Distilled has published on Beam Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-04-24 Watch Beam Therapeutics (BEAM) - Scientific Deep Dive for Risto-cel and Pipeline Products The base editing science is undeniable and the balance sheet is a fortress, but the smart move is to wait for FDA reaction to Grade 4 ALT elevations in the BEAM-302 multi-dose cohort before taking a heavy position.
- 2026-06-18 Watch UPDATE: Beam Therapeutics (BEAM) - The Third Liver Bet Goes Clinical PKU IND clearance is a thesis-tracking checkpoint but not a re-rating event; the binding constraint of LNP hepatotoxicity in BEAM-302's multi-dose cohort remains unresolved, so no position is warranted yet.
- 2026-08-04 Watch UPDATE: Beam Therapeutics (BEAM) - The Pivotal Cohort Opens, The Stock Doesn't Care Pivotal cohort dosing and BEACON completion are positive execution checkpoints, but the LNP hepatotoxicity question is still unproven at scale and the runway is now milestone-gated; the ERS readout in five weeks is the defined catalyst before deploying capital.
- 2026-09-08 Speculative buy speculative UPDATE: Beam Therapeutics (BEAM) - Barcelona Answers the Liver Question The single dominant failure mode — LNP hepatotoxicity — read out clean at n=29 with no Grade 4 events and 18-month durability covering the approval endpoint, shifting remaining risks to regulatory and commercial rather than existential-biological.
- 2026-10-14 Speculative buy speculative UPDATE: Beam Therapeutics (BEAM) - The Second Liver Bet Shows Its Hand A second liver program on the same LNP showed no transaminase elevation above Grade 2 and a tangible efficacy signal, reinforcing the vehicle de-risking thesis, though n=5 and thin follow-up prevent a label upgrade.
- 2026-10-28 Speculative buy speculative UPDATE: Beam Therapeutics (BEAM) - Off the Cornstarch Two of three 40 mg GSDIa patients achieved full starch independence with a quiet liver on the shared LNP, deepening the vehicle de-risking case, but one non-responder, serious IRRs, and an untested premedication fix keep conviction at speculative.
- 2026-11-11 Speculative buy speculative UPDATE: Beam Therapeutics (BEAM) - The Permission Slip Gets Signed BEACON meeting its pivotal VF12 endpoint retires risto-cel's clinical risk and supports a year-end BLA and milestone-gated debt draws, but the upgrade was on the liver vehicle and today is reinforcement of the near-term leg, not a new category of evidence.
- Long call · opened Sep 9, 2026 at $25.18 · -18.0% vs XBI -8.8% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (1 quote from 1 filing)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
““We are approaching a potential first BLA filing with risto-cel as early as the end of this year, and the pivotal cohort for BEAM-302 is rapidly advancing with completion of dosing expected in the first half of 2027.”
matched to risto-cel · regulatory submission
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (25)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 7, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 10, 2026ReleaseBeam Therapeutics Announces Positive Topline Pivotal Data from BEACON Phase 1/2 Trial of Risto-cel in Patients with Sickle Cell Disease→ BD updateBEACON's pivotal interim cleared the bar — 31 of 49 patients free from severe VOCs for 12 straight months — and the BLA is coming year-end. The stock sold off 6.9% anyway, repricing a permission slip, not a commercial win.
- Nov 4, 2026ReleaseBeam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual Meeting
- Nov 3, 2026ReleaseBeam Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress Across Base Editing Portfolio
- Nov 3, 20268-KCurrent report: results of operations · EX-99.1
- Nov 3, 202610-QQuarterly report
- Oct 27, 2026ReleaseBeam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual→ BD updateBEAM-301's ESGCT poster delivers the answers the October 13 update asked for: two 40 mg patients are now completely off cornstarch, the non-responder has a mechanistic explanation, the 60 mg cohort is enrolling, and Beam is engaging the FDA on an approval path — all on the same clean-liver-enzyme story that has anchored the platform thesis.BD extracted 1 program update from this document → BEAM pipeline
- Oct 13, 2026ReleaseBeam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress→ BD updateBEAM-301's first-in-human data in GSDIa delivers a genuine functional proof of concept — 40 mg patients achieved ≥15 hours of controlled fasting from a 2.5-hour baseline, with ~80-92% starch reductions — and the LNP safety profile held, extending the platform de-risking story that Barcelona started in September.BD extracted 1 program update from this document → BEAM pipeline
- Sep 8, 2026ReleaseBeam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026→ BD updateThe ERS late-breaker landed: BEAM-302's single-dose data held clean across 29 patients and up to 18 months of follow-up — the hepatotoxicity overhang that defined the bear case looks materially narrower than it did five weeks ago, and the pivotal cohort is already dosing.
- Sep 1, 2026ReleaseBeam Therapeutics Appoints Eric Foster as Chief Commercial Officer
- Aug 31, 2026ReleaseBeam Therapeutics to Participate in Upcoming September 2026 Investor Conferences
- Aug 4, 2026ReleaseBeam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)BD extracted 2 program updates from this document → BEAM pipeline
- Aug 4, 20268-KCurrent report: results of operations · EX-99.1
- Aug 4, 202610-QQuarterly report
- Jul 23, 2026ReleaseBeam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) CongresBD extracted 1 program update from this document → BEAM pipeline
- Jun 18, 2026ReleaseBeam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug AdministrationBD extracted 1 program update from this document → BEAM pipeline
- Jun 8, 20268-KCurrent report: shareholder vote
- May 18, 2026ReleaseBeam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
- May 13, 2026ReleaseBeam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference
- May 12, 2026ReleaseBeam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026
- May 7, 2026ReleaseBeam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
- May 7, 20268-KCurrent report: results of operations · EX-99.1
- May 7, 202610-QQuarterly report
- Apr 17, 2026DEFA14AProxy soliciting material
- Apr 17, 2026DEF 14AProxy statement
- Mar 5, 20268-KCurrent report: agreement terminated
6 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 13, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 13, 2026SCHEDULE 13G/A13G amendment
- Apr 29, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 17, 2026ARSAnnual report to shareholders
- Mar 26, 2026SCHEDULE 13G/A13G amendment